KLOW Blend 80mg

KLOW Blend 80mg

KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in one peptide blend. Research on individual ingredients explores collagen production, tissue repair processes and inflammatory signalling. KLOW is used by both people looking to recover from injuries or physical activity, but also those seeking cleaner, clearer skin. KLOW blend adds KPV to the existing GLOW blend, KPV helps with inflamation.

Apply for a Trade Account

SEQUORA KLOW Blend 80mg is a four-compound Peptide blend containing 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV. Available in vial and prefilled pen formats, KLOW’s research explores processes involved in tissue repair, collagen production and inflammatory signalling, including skin, tendon and intestinal research models.

Choose your product format
  • 80mg vial: an 80mg sealed vial of lyophilized powder (freeze dried). This format extends the shelf-life significantly and also allows freezer storage of your KLOW Blend. This vial can then be mixed with Bacteriostatic Water (BAC water) and be used as an injectable KLOW compound.
  • 80mg prefilled pen: A prepared reconstituted KLOW Blend in a 3ml cartridge. This is then inserted into a SEQUORA disposable injector pen for easy use and dosing.

The 80mg figure indicates the total stated content across all four compounds, not the concentration or amount delivered per withdrawal. Review the specifications for your selected format.

Purity & Verification

All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.

What is KLOW Blend 80mg used For?

KLOW is used to aid with Tissue Repair & Inflammation. It’s active Ingredients include BPC-157 and TB-500 which are researched for their healing and repair signalling as well as GHK-Cu Copper Tripeptide which aids with Collagen production and tissue remodelling it also has 10mg of KPV which reduces inflammatory signalling in the body.

What are the benefits of KLOW Blend 80mg?

KLOW is known to boost skin vitality, aid with injury and tendon/ligament damage repair and reduce inflammation, especially in the intestines and gut. It is used by both men and women for it’s longevity boosting benefits and body recovery.

Why buy KLOW Blend 80mg from SEQUORA?

SEQUORA’s KLOW blend is accurately dosed, providing 50mg of GHK-Cu, 10mg of BPC 157, 10mg of TB-500 and 10mg of KPV. We test all of our peptides for purity but also accurate dosing which can be found in the SEQUORA KLOW test summary.

Questions & Answers

What Is the KLOW Peptide Blend?

KLOW is GLOW plus KPV, which makes it a four-peptide blend. KPV is a short peptide that the FDA lists among substances nominated for compounding, and its regulatory story is covered in the status section below. The other three ingredients are identical in both products.

KPV’s main benefit is inflammation battling properties, so if this isn’t something you’re looking to treat or suffer with, then GLOW will have the same benefits as KLOW at a smaller price point.

KLOW’s characteristic blue colour comes from GHK-Cu, the copper peptide in the blend. GHK is a three-amino-acid peptide that binds to a copper ion. This complex absorbs certain wavelengths of visible light, giving it its blue appearance.

SEQUORA KLOW contains 50mg of GHK-Cu within its 70mg peptide blend, making it approximately 71% of the stated peptide content. BPC-157 and TB-500 do not normally contribute a blue colour.

The freeze-dried powder may appear pale blue, while a dissolved solution can look clear blue. Its appearance varies with concentration, formulation and lighting.

What Is KLOW Used For?

Tissue Repair and Recovery Research

SEQUORA KLOW combines compounds whose individual benefits include wound healing, tendon repair and inflammatory signalling. BPC-157 has been investigated in injury models, while thymosin-related research explores cellular processes associated with repair.

A Combined Research Blend

KLOW brings BPC-157, TB-500, KPV and GHK-Cu together in one formulation. Each ingredient has a different research background, but combining them does not demonstrate greater effectiveness than studying them separately.

Skin and Connective Tissue Research

GHK-Cu is studied for its role in collagen production and tissue remodelling. Laboratory studies have explored its effects on fibroblasts, the cells involved in forming and maintaining connective tissue.

Intestinal and Inflammation Research

BPC-157 and KPV have been investigated in experimental gastrointestinal research. KPV studies include intestinal cells and mouse models of inflammation, while BPC-157 research includes gastrointestinal protection and repair models.

Side effects come from clinical trials and patient studies and are not confirmed medically. Injection site reactions are the most frequent as that’s a normal reaction to GHK-Cu and mild sensitivity or soreness around the injection site.

  • Anyone with a copper sensitivity or Wilson Disease should not use KLOW.
  • Anyone with active cancer or a recent cancer history should not use KLOW down to several of its components acting on blood vessel growth and cell migration.
  • ibuprofen, naproxen, and aspirin all conflict with the protocol, including the versions hiding inside cold and headache combination products.

Product Information Guide

KLOW

Product information, handling and safety

Storage

What Temperature should I store my KLOW at?

Safety

What are the best practices for using KLOW safely?

Evidence

The documentation behind KLOW and it's uses

What is KLOW?

KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in one peptide blend. Research on individual ingredients explores collagen production, tissue repair processes and inflammatory signalling. KLOW is used by both people looking to recover from injuries or physical activity, but also those seeking cleaner, clearer skin. KLOW blend adds KPV to the existing GLOW blend, KPV helps with inflamation.

Storage & Handling

Storage

Upon delivery store in a refridgerator between 2-8°C.

  • Avoid storing at the very back of the refridgerator.
  • Avoid exposure to heat, direct sunlight and temperature fluctuations.
  • Never freeze your SEQUORA KLOW Pens (Vials are safe to be frozen BEFORE reconstitution only).

Handling

Avoid dropping or heavy-handling of your KLOW Blend.

Please do not freeze your SEQUORA KLOW Pen as this can compromise the individual peptides.

Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.

shelf-life

Your SEQUORA KLOW Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.

SEQUORA KLOW Blend Vials before reconstitution can last up to 4 years at -5°C

KLOW can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.

Safety & Hygiene

pre-use hygiene

Before handling your KLOW, needles or injection material, ensure your research area is clean and clear.

Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.

If at any point the cleanliness of your injection or environment is compromised, restart this step.

needle & injection safety

Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.

Before using your SEQUORA KLOW Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.

If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.

post-injection guidance

Ensure that your needle tips, syringes and vials are safely disposed of post-use.

This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.

Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.

Potential KLOW Side Effects

KLOW combines GHK-Cu, KPV, BPC-157 and TB-500. Its safety profile as a combined injectable product has not been established. The experiences below include unverified reports from people describing their own use, not controlled clinical findings.

Effects described in individual user reports

  • Stinging, burning or soreness at the injection site, sometimes lasting into the following day
  • Tingling or increased skin sensitivity around the injection area
  • Possible spots or breakouts, although the person reporting these was unsure whether KLOW caused them
  • Dry mouth or an unusual taste shortly after administration
  • Increased alertness or feeling unusually stimulated
  • Anxiety, disturbed sleep, palpitations, shivering or a sensation of not getting enough air

How to interpret these reports

These accounts cannot establish how frequently symptoms occur or whether KLOW caused them. Product identity, concentration, sterility and other substances used were not independently verified. One report involving anxiety, palpitations and breathing discomfort also described pre-workout and beetroot supplement use.

It is not possible to reliably assign a reported symptom to GHK-Cu, KPV, BPC-157 or TB-500 from a blend user’s experience alone.

Other important risks and uncertainties

Human safety information for these ingredients is limited or absent for relevant injectable preparations. Regulatory concerns include immune reactions, peptide aggregation and impurities. Evidence about individual ingredients does not establish the compatibility, stability or safety of combining them.

Injection introduces additional risks, including infection, abscess formation and tissue injury. Long-term effects and interactions with medicines remain uncertain.

When to seek medical advice

Stop use and seek prompt medical advice for persistent burning, worsening pain, a new rash, recurrent palpitations or significant changes in mood or sleep. Increasing redness, warmth, swelling, discharge or fever requires prompt assessment for possible infection.

Symptoms requiring emergency help

Call 999 for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain or collapse. Palpitations accompanied by breathlessness, chest pain or fainting also require emergency assessment. Do not assume these symptoms are simply anxiety.

About this information

This summary combines regulatory safety concerns with clearly identified personal reports. Those reports are not verified adverse reactions to SEQUORA products. This information does not establish product safety or suitability for human use and does not replace medical advice.

KLOW Side Effect Mitigation

No mitigation protocol has been established that makes the KLOW blend safe. The following information addresses symptoms described in individual reports and general risks of injecting unapproved products. It is not a recommendation to continue using a product that causes symptoms.

Injection-site burning or skin sensitivity

  • Stop use if burning is persistent, severe or worsening. Do not assume it indicates that the product is working.
  • Do not inject into skin that is already painful, inflamed, bruised or damaged.
  • Seek assessment for increasing redness, warmth, swelling, discharge or fever.
  • Do not attempt to correct irritation by adding more water, changing the solution’s pH or mixing in other substances without professional guidance.

In one firsthand report, allowing the solution to reach room temperature, letting skin-cleansing alcohol dry and changing injection sites did not resolve prolonged burning. These measures should not be presented as reliable solutions to a reaction.

Dry mouth or an unusual taste

  • Small sips of water may help relieve dry mouth unless you have been advised to restrict fluids.
  • Report persistent or recurrent symptoms to a healthcare professional.
  • Do not interpret an immediate taste or dry mouth as proof of product purity or correct administration.

Feeling stimulated, anxiety or disturbed sleep

  • Stop use and seek advice if new symptoms develop.
  • Avoid adding caffeine, stimulant pre-workouts or other non-prescribed stimulants while symptoms are being assessed.
  • Do not try to counteract symptoms with sedatives, alcohol or additional research compounds.
  • Do not assume moving administration to another time of day makes the reaction safe.

Palpitations or breathing discomfort

Stop use and seek medical assessment. These symptoms should not be managed solely by changing the dose, dilution or schedule. Call 999 if palpitations occur with chest pain, shortness of breath or fainting, or if breathing difficulty is significant.

Avoid unproven corrective measures

  • Do not assume symptoms are a detox reaction, a healing response or something that must be tolerated.
  • Do not start high-dose zinc, copper supplements or chelation treatments to counter suspected copper-related effects without medical assessment.
  • Do not take another dose simply to test whether a suspected reaction happens again.
  • Avoid introducing additional compounds, which can add risks and make the cause of symptoms harder to identify.

Reduce contamination and recording errors

  • Never share or reuse needles or syringes.
  • Do not use a vial with suspected contamination or damaged packaging. A clear appearance does not establish sterility.
  • Keep the packaging, batch details and a record of the amount used, timing, symptoms and other medicines or supplements taken.
  • Share this information with the healthcare professional assessing the reaction.

About this information

Personal reports can identify concerns worth investigating, but they cannot establish a safe dose or an effective mitigation strategy. These measures do not validate the blend’s compatibility, stability, sterility or suitability for injection and do not replace individual medical advice.

Dosing Guidance For KLOW Blend 80mg

The KLOW Blend has a typical structure of 4-6 weeks “on-cycle” and 2-4 weeks “off-cycle”, this is mainly due to the copper accumulation from GHK-Cu.

KLOW Should be injected DAILY. Always confirm the pens strength before each administration.

Calculation basis: 80 mg total blend in a final volume of 3 ml, with 0.01 ml delivered per pen dial unit. “Dose” shows the nominal amount; “Total Dose” shows the calculated amount at the listed setting.

Dose Phase 80mg Pen Dial Setting Total Dose Breakdown of doses
2 mg Weeks 1–2 8 ≈2.133 mg total blend GHK-Cu: ≈1.333 mg / KPV: ≈267 mcg / BPC-157: ≈267 mcg / TB-500: ≈267 mcg
4 mg Weeks 3–4 15 4 mg total blend GHK-Cu: 2.5 mg / KPV: 500 mcg / BPC-157: 500 mcg / TB-500: 500 mcg
6 mg Weeks 5–8 23 ≈6.133 mg total blend GHK-Cu: ≈3.833 mg / KPV: ≈767 mcg / BPC-157: ≈767 mcg / TB-500: ≈767 mcg
4 mg Weeks 9–12 (taper) 15 4 mg total blend GHK-Cu: 2.5 mg / KPV: 500 mcg / BPC-157: 500 mcg / TB-500: 500 mcg

Understanding the figures

Doses are expressed in milligrams per daily administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 80mg KLOW Pen contains 3ml of reconstituted KLOW meaning every 1 dial = Approximately 0.2667 mg of KLOW Blend (166.7 mcg of GHK-Cu / 33.3 mcg of KPV, BPC-157 and TB-500).